Sanofi-Aventis Pakistan Limited Pharmaceuticals vs Glaxosmithkline

Effects of Quality steering on Domestic and Global Competition In Pakistan, Sanofi-Aventis and GlaxoSmithKline are pharmaceutic companies that market place popular products and carry very similar medications. Companies like these view the mission and responsibility of providing medicines and vaccinations to better spates live in different countries and communities. One of the largest and leading pharmaceutic companies in Pakistan is the Sanofi-Aventis Pakistan Limited.The chains pitch most of their focus on therapeutic areas such as cardiovascular, thrombosis, oncology, fundamental nervous systems function, metabolic disorders, internal medicine, and vaccinations (Sanofi, 2010). GlaxoSmithKline is also kn aver for developing several(prenominal) of the nations leading global medicines in the fields of human immunodeficiency virus/AIDS, tuberculosis, and malaria. The strategic management methods this manufacturer has chosen to use has make them a leader in the industry, among its competitors with respect to changing markets and exploitation trends.In 2007, the soma one rated pharmaceutical fellowship was GlaxoSmithKline, which has fount its glide byd success in making very wise business decisions like delivering almost 1 billion vaccines to developing countries in 2009 (GlaxoSmithKline, 2010). Diseases such as cardiovascular issues, thrombosis, backcer, diabetes, human immunodeficiency virus/AIDS, malaria, and an another(prenominal)(prenominal) major illnesses learn been crucial public health issues for Pakistan because they puzzle been proved to be a main contributor to the total global mortality rates.It is for this reason that companies like Sanofi-Aventis and GlaxoSmithKline have concentrated so ofttimes of their research efforts on those specific issues and areas. The result has resulted in a world-renowned theme of expertise for both in the industry. The following paper will exempt why the medications that are produced by the companies above are competitive in both domestic and global markets, and it will compare and contrast the case management for these two organizations.Sanofi-Aventis is a multi-national organization and is currently the third-largest pharmaceutical group both France and Europe. It is an all-inclusive business as it conducts research, development, manufacturing, marketing the have pharmaceuticals, and the company was formed in 2004 when the initial company, Sanofi-Synthelabo, bought out Aventis. Aventis had originally spurned the bids, and this turned into a three-month war until Sanofi-Synthelabo at last offered the acceptable bid of $54. 5 billion (Sanofi, 2010).After the bidding war was over, the Chairman of Sanofi-Aventis, Jean-Francois Dehecq, and the CEO, Gerard Le Fur, started the action of emphasizing the importance of customer religious service and their loading to excellent service for the people who relied on their medications. Over the last several years, pricing and other va rious competitive methods and strategies of companies like these have been changing with technological developments, stinting changes, federal legislation, and state drug substitution laws (Federal, 2010).With these impending changes, the overall market has undergone structural transformations as well that include the growth of the market for generic wine drugs, and company consolidations. The nature of this kind of competition is naturally subject to continual globally institutional and structural changes. GlaxoSmithKline has had a very notable bill in the pharmaceutical industry as well since the early eighteenth century, and they are headquartered in the U. K. This company conducts business in the U. S. and boasts an estimated seven share of the worlds total pharmaceutical market.Both companys visions and plans were to become new, progressive companies were with great enthusiasm and vigor, as they had a elucidate vision of the desire to motivate the employees in almost 100 c ountries. Luckily, they already demonstrated an extensive portfolio of cutting-edge medications, reliable service to their patients and an overall commitment to the tint of life, so these factors enabled the company to continue to achieve their performance goals and gratify the responsibilities they had to their communities.Coupled with evolving information technology and regular industry changes, there was and continues to be an increasing benefit and need for companies to choose and then charge differing prices to people in corresponding economic brackets. The competitive implications of these differential pricing manoeuvre have offered companies like Sanofi-Aventi and GlaxoSmithKline the opportunities to spread their business over larger areas, much hospitals, and to involve themselves in other segments of demand by making themselves more flexible in the industry.These kinds of practices have probably changed the way they have partly because specific types of buyers as well as manufacturers have adopted and apply cost-controlling measures that are similar to those that have been used by traditional hospitals (Federal, 2010). The Sanofi-Aventis industrial Affairs organization has been proven to be totally committed to providing the highest quality of service to its customers and patients, taking into consideration all of the current protocols of the Good Manufacturing Practices (GMP) the company takes from its plants that are based at Karachi & Wah Cantt (Sanofi, 2010).As with almost any other organization, quality and the amount of productivity are very important and on a regular basis monitored, and there is a great emphasis placed on maintaining wellness and Safety codes in order to fall out the employees safe on the job. During 2005, the industrial Affairs department of Sanofi-Aventis continued to focus on committing their time and sinew to providing the highest quality of customer service, while meeting their own production goals.GlaxoSmithKlin e has been experiencing their own specific challenges due to regulatory issues, patent of invention expiration issues, and increased pressures that are coming from different healthcare providers that have created an environment of tension, lower growth rates, and higher risk for the company. They are addressing these challenges with three priorities grow and expand on a diversified global business foundation, delivering quality products of high value, and finally simplifying the general operating model.The Pakistani pharmaceutical market has been and remains to be weighed down with financial and producing difficulties. Government regulations and control over fixed prices has made many of the drugs offered unaffordable to consumers, and this has resulted in people searching for what they need on the murky market at increased prices, or the drugs have just disappeared completely.In this kind of high-tension environment, both global manufacturers and local foreign-owned companies hav e proven that they are not able to make the profits needed for bang-up investment. Currently, there are no formal public drug reimbursement programs, although patent laws became more regulated in December 2000 (Sanofi, 2010). In the year 2002, Pakistans regulation laws became even weaker than they had been.In reaction to this, the formation and recruitments of drug watch teams were brought in to investigate the manufacturing and gross sales of fraudulent drugs, but unfortunately have not had satisfactory results so far, largely due to a lose of necessary resources and various bureaucratic complications. Though both Sanofi-Aventis and GlaxoSmithKline have been slimy from the declines of sales and the resulting losses in profitability for the past few years, the companies continue to make every effort to not only regain their positions in the industry, but to exceed expectations.The ways in which quality management can have major affects on the current position of both of these c ompanies in both a domestic and the global market are to keep their focus on their core competitive edge and to work to get ahead improve its internal controls within each company. The sales forces for any pharmaceutical company are considered to be the back-bone of the industry, and both companies will most liable(predicate) begin to thrive when they create and develop a successful sales force to improve their future prospects as the economy improves